ArticleFrontiers in molecular neuroscience2026
Integrative genomic analysis identifies key target genes and candidate drugs for spinal stenosis.
Article in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spinal stenosis is a common pathological condition characterized by the narrowing of the spinal canal, contributing to substantial morbidity and imposing a significant socioeconomic burden. Despite its clinical importance, the genetic drivers and cellular mechanisms driving its progression remain inadequately understood, necessitating integrative approaches to identify therapeutic targets. Methods: This study employed an integrative multi-omics strategy. Initially, summary-data-based Mendelian randomization was conducted using cis-expression quantitative trait loci data from 19,960 genes alongside spinal stenosis genome-wide association study data. Gene-gene interaction networks and colocalization analyses further refined candidate genes. Additionally, single-cell RNA sequencing of spinal tissues was performed to assess cellular enrichment, and molecular docking was employed to screened FDA-approved drugs against prioritized targets. Immunohistochemistry (IHC), Western blot (WB), and quantitative real-time PCR (qRT-PCR) were conducted using tissue samples and primary cells to validate the bioinformatics analysis results. Results: SMR analysis identified 45 candidate target genes, which were further narrowed to three key genes including KAT5, TET2, and TAF10 through gene-gene interaction analysis and colocalization. Single-cell RNA sequencing revealed that these genes were predominantly enriched in chondrocytes and monocytes, implicating cellular cross-talk via the TGF-β1- (TGF-βR1 ++ TGF-βR2) pathway, a driver of fibrosis and ossification. Molecular docking identified six high-affinity compounds: Balsalazide and Eltrombopag for KAT5, Magnesium Citrate and Ferric Citrate for TET2, and Piracetam and Deferiprone for TAF10. The expression level of KAT5 and TET10 were both consistent with our SMR analysis in both tissues and primary cells. Conclusion: These findings elucidate novel genetic and cellular mechanisms underlying spinal stenosis, highlighting the role of TGF-β pathway in disease progression. The identified compounds offer promising therapeutic interventions, bridging genomic discoveries to clinical applications and paving the way for targeted treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.